More Study Needed of Possible Carcinogenesis of Winter Gas Additive

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--Although the chemical MTBE, added to gasoline in the winter to reduce the emission of carbon monoxide, does not pose a substantial human health risk, more study needs to be undertaken to assess both short- and long-term health effects, a National Research Council (NRC) committee said in its review of a draft of a federal report.

WASHINGTON--Although the chemical MTBE, added to gasoline in thewinter to reduce the emission of carbon monoxide, does not posea substantial human health risk, more study needs to be undertakento assess both short- and long-term health effects, a NationalResearch Council (NRC) committee said in its review of a draftof a federal report.

The federal study assessed the effects of methyl-tertiary-butylether (MTBE) on air and water quality, motor vehicles (fuel economyand engine performance), and public health.

In areas that have not met air quality standards for carbon monoxide,federal law requires the use of additives that increase oxygenlevels in gas during winter months when lower temperatures tendto cause vehicles to emit more carbon monoxide. However, availabledata indicate that oxygenated fuels reduce winter air levels ofcarbon monoxide by as little as 0% to about 10%, the committeesaid.

The NRC committee disagreed with the report's conclusion thatonly a small percentage of the population may be sensitive toMTBE, citing studies showing an increase in health problems amongworkers exposed to MTBE on the job.

In addition, the panel said, cancer estimates for MTBE were basedon animal models and should not be taken as conclusive. The committeerecommended that further investigations be made into MTBE as apotential carcinogen.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.